Personalized Approaches to Immune Disorders
Publisher
Springer New York
Reference14 articles.
1. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782–9.
2. Fu Liang NG, Holt DW, MacPhee I. Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. Expert Opin Pharmacother. 2007;8:2045–58.
3. Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2014; pii: annrheumdis-2013-204986.
4. Hronová K, Šíma M, Světlík S, et al. Pharmacogenetics and immunosuppressive drugs. Expert Rev Clin Pharmacol. 2014;7:821–35.
5. Huizinga TW. Personalized medicine in rheumatoid arthritis: is the glass half full or half empty. J Int Med. 2014. doi:
10.1111/joim.12319
.